SELENTUS DEVELOPS MEDICAL DEVICES FOR SURGICAL BLEEDING AND WOUND THERAPY
Approved for sale in Europe
Haemostatic absorbable gelatine sponge with surface modification for increased tissue adhesion
Patents granted in U.K. (GB 2543307), U.S.A (US 10,653,821), Europe (EP 3362110), Japan (JP 6854825), Brazil (BR 112018007612-0 B1) and China (CN 108136080 B) and pending worldwide
Selentus develops innovative haemostatic technologies for better surgical outcomes. Selentus is developing a pipeline of products based on its unique technology platform that offer high performance, low cost manufacture and avoid the use of blood-derived materials. Selentus' lead product, TenaTac®, was approved for sale in Europe in September 2019 and is licensed to CuraMedrix B.V. in Europe and selected ROW territories.
Please click below to request further information on territories available for partnership, or to purchase TenaTac® in Europe:
This website is intended for healthcare professionals. TenaTac® is approved for use in Europe. TenaTac® is not approved for use in the USA.